Navigation Links
Vapotherm Announces Commercial Launch of Flowrest® Homecare Device

STEVENSVILLE, Md., July 26, 2011 /PRNewswire-USNewswire/ -- Vapotherm announced today the launch of Flowrest®, a High Flow Therapy device developed specifically for homecare and other low acuity environments. The initial launch will focus on the U.S. and European markets.

Vapotherm's Flowrest® is designed specifically for chronic respiratory patients in home and other extended care environments.  According to the World Health Organization, chronic respiratory diseases impact hundreds of millions of people worldwide, with asthma and COPD alone totaling almost 300 million globally.  Other chronic conditions include allergic rhinitis, pulmonary fibrosis and pulmonary hypertension.  In the U.S. alone, COPD affects more than 16 million and over 1 million patients are prescribed long-term oxygen therapy.  Flowrest® is indicated to deliver heated, humidified breathing gases via nasal cannula at flow rates from 15 to 35 liters per minute.

"In response to pre-launch demand, we are excited to begin shipping Flowrest® to our customers in the U.S. and Europe," said Nick Macmillan, Home Care Segment Manager at Vapotherm.  "The Flowrest® provides patients with a new option for respiratory assistance that overcomes the well documented issues associated with mask therapies including problems with patient compliance and comfort.  Through our patented technology, we have empowered the simple and comfortable nasal cannula to provide higher levels of respiratory support."

Robert Storey, CEO of Vapotherm, commenting on the launch stated, "We wanted to provide a solution to the constant requests we received from hospital customers for a homecare option.  Worldwide, health care systems are looking for ways to get patients out of the hospital faster and sustain them at home to minimize the risk that they will have to return to the hospital.  Flowrest® is our answer to the continuity of care in High Flow Therapy."

Vapotherm has been the leading provider of High Flow Therapy devices to hospitals for over ten years, and created the category of High Flow Nasal Cannula beginning in 2001 with its first device, the 2000i.  The Company's flagship product, the Precision Flow®, is currently used in hospitals worldwide in adult, pediatric and neonatal applications.  The Flowrest® was created to fill the need for High Flow Therapy outside of the short term acute care environment.

Vapotherm, Inc. is a privately held manufacturer of respiratory care devices for hospitals and homecare use based in Stevensville, Maryland. The Company is dedicated to the development of innovative, noninvasive respiratory therapy technologies, especially for the treatment of acute and chronic breathing disorders. For more information, visit

Vapotherm, Inc.
198 Log Canoe Circle
Stevensville, MD 21666
Phone (410) 604-3977
Fax (410) 604-3978

Contact:  Kevin Thibodeau, Executive Vice President of Sales and Marketing

SOURCE Vapotherm, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vapotherm Announces Approval in Canada for New High Flow Device Designed for Heliox
2. Vapotherm Announces New Exclusive Distribution Agreement with Hippo Medical for South Korea
3. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
4. Vapotherm, Inc. Announces CE Mark Approval for Flowrest® Homecare Device
5. Accuray Announces Proposed Offering of $75 Million Convertible Senior Notes
6. arGEN-X Announces Non-Exclusive License With BioWa for POTELLIGENT® Technology
7. NuMe Health Announces Closing of Series A-1 Financing Round
8. Amgen Announces Webcast of 2011 Second Quarter Financial Results
9. Lanx, Inc. Announces Aspen™ Spinous Process Fixation System Clinical Data at IMAST
10. Prasco® Announces Authorized Generic Agreement with Shionogi Inc.
11. Cornerstone Pharmaceuticals Announces The Journal of Molecular Medicines Publication of Research Showing Selective Inhibition of Cancer Cell Energy Metabolism With Its Novel Lipoate Derivative Compounds
Post Your Comments:
(Date:11/30/2015)... Die MEDTEC Japan 2016, ... Entwicklung und Herstellung medizinischer Geräte, findet ... in Tokyo ... Foto: ... --> ...
(Date:11/30/2015)... , Nov. 30, 2015 Nevro Corp. (NYSE: ... providing innovative evidence-based solutions for the treatment of chronic pain, ... at the U.S. Patent and Trademark Office (USPTO) has denied ... Patent No. 8,359,102 (the ,102 patent).  ... unit of Boston Scientific Corporation filed two petitions challenging the ...
(Date:11/30/2015)... , Nov. 30, 2015   Royal ... announced the launch of Radiology Solutions, a fully ... Radiology Solutions comprises customized, data-driven practice management approaches ... to help radiology practices improve care delivery and ... 2015 Radiological Society of North America Annual Meeting ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... ... According to research by the National Association of Dental ... certified or obtain continuing education. To increase awareness of the lack of standards ... inform dentists that the technicians they trust could lack the skills and knowledge ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... The directory is specialized and only includes chiropractic clinics in the US. , ... and trustworthy alternative health practitioner when back pain sets in. When people are ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... experience this summer, ushering in a new era of publicly accessible automated technology. ... shuttle, will continue to offer guests an up-close look at the shuttle at ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... for Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted ... featuring a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort ... to access life-saving information provided directly from top experts in mesothelioma, in ... individual conferences in three major cities: Houston, San Francisco, and Chicago. , ...
Breaking Medicine News(10 mins):